(redirected from Antibody-dependent cellular cytotoxicity)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to Antibody-dependent cellular cytotoxicity: antibody-dependent cell-mediated cytotoxicity (ADCC)
Category filter:
ADCCAntibody-Dependent Cellular Cytotoxicity
ADCCAntibody-Dependent Cell-Mediated Cytotoxicity
ADCCAbu Dhabi Combat Club (wrestling)
ADCCAdenoid Cystic Carcinoma (gland tumor)
ADCCAdvertising and Design Club of Canada (Toronto, Ontario, Canada)
ADCCAlzheimer's Disease Core Center
ADCCAdrenocortical Carcinoma
ADCCAir Defense Control Center
ADCCAvoiding Dangerous Climate Change (conference)
ADCCAutomated Dispensing Cabinet (drug dispensing)
ADCCAsia-Pacific Development Communication Centre (Dhurakij Pundit University; Bangkok, Thailand)
ADCCArctic System Science Data Coordination Center (ARCSS)
ADCCAntibody Dependent Cytotoxic Cell
ADCCAdvanced Data Communication Control
ADCCAir Defense Command & Control
ADCCAsynchronous Data Communications Controller
ADCCAccess Data Consulting Corporation (Greenwood Village, CO)
ADCCAir Defense Coordination Center
ADCCAssociation des Descendants de Capitaines Corsaires (France)
ADCCAbu Dhabi Construction Company (United Arab Emirates)
ADCCAdmiral Drake Cricket Club (UK)
ADCCANZAC (Australian and New Zealand Army Corps) Day Commemoration Committee (Australia)
ADCCAlzheimer's Disease Care Clinic
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Preclinice I in-vitro studies showed that this second-generation nonfucosylated anti-CD30 antibody demonstrated enhanced ADCC (antibody-dependent cellular cytotoxicity), an important mechanism of action of therapeutic antibodies, and was active in inhibiting tumour growth in in-vivo xenograft models.
HuMax-ZP3 potently exhibits the Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement Dependent Cytotoxicity (CDC) immune system killing mechanisms against ZP3-expressing tumor cells, Genmab said.
Targeting cancer-specific membrane protein owned by OncoTherapy, the two companies will create an antibody with improved ADCC (antibody-dependent cellular cytotoxicity) activity using BioWa's proprietary antibody technology POTELLIGENT.
It is based on an active modulation of antibody glycosylation during production leading to antibody products with increased ADCC (antibody-dependent cellular cytotoxicity).
Full browser ?